AMGEN INC

NASDAQ: AMGN (Amgen Inc.)

Kemas kini terakhir: semalam, 3:40PM

285.98

4.57 (1.62%)

  • 1H 1.62%
  • 5H -2.86%
  • 1B -8.84%
  • 6B -11.90%
  • Tahun Ke Tarikh 10.30%
  • 1T 7.71%
  • 5T 26.09%
Penutupan Terdahulu 281.41
Buka 283.13
Jumlah Dagangan 3,467,087
Purata Dagangan (3B) 3,279,835
Modal Pasaran 153,757,433,856
Harga / Pendapatan (P/E TTM) 37.88
Harga / Pendapatan (P/E Ke hadapan) 13.83
Harga / Jualan (P/S) 4.63
Harga / Buku (P/B) 26.14
Julat 52 Minggu
253.30 (-11%) — 346.85 (21%)
Tarikh Pendapatan 1 May 2025
Hasil Dividen (DY TTM) 3.19%
Margin Keuntungan 12.24%
Margin Operasi (TTM) 51.81%
EPS Cair (TTM) 7.55
Pertumbuhan Hasil Suku Tahunan (YOY) 10.90%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -18.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 1,035.89%
Nisbah Semasa (MRQ) 1.26
Aliran Tunai Operasi (OCF TTM) 11.49 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 13.73 B
Pulangan Atas Aset (ROA TTM) 6.40%
Pulangan Atas Ekuiti (ROE TTM) 67.55%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Menaik
Drug Manufacturers - General (Global) Bercampur Menaik
Stok Amgen Inc. Menaik Menaik

AISkor Stockmoo

1.1
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 1.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AMGN 154 B 3.19% 37.88 26.14
GILD 133 B 2.91% 273.08 6.68
AZN 230 B 2.26% 30.43 6.19
SNY 127 B 7.86% 21.51 1.48
GRFS 6 B - 28.00 0.710
BIIB 21 B - 12.64 1.01

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.22%
% Dimiliki oleh Institusi 82.03%
345.10345.10311.80311.80278.50278.50245.20245.20211.90211.90Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
253.30 (-11%) — 346.85 (21%)
Julat Harga Sasaran
294.00 (2%) — 330.00 (15%)
Tinggi 330.00 (Morgan Stanley, 15.39%) Pegang
Median 324.00 (13.30%)
Rendah 294.00 (B of A Securities, 2.80%) Jual
Purata 314.40 (9.94%)
Jumlah 2 Beli, 2 Pegang, 1 Jual
Harga Purata @ Panggilan 291.63
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Morgan Stanley 09 Apr 2025 330.00 (15.39%) Pegang 291.09
B of A Securities 05 Mar 2025 294.00 (2.80%) Jual 316.57
06 Feb 2025 275.00 (-3.84%) Jual 297.78
Piper Sandler 10 Feb 2025 329.00 (15.04%) Beli 294.79
Citigroup 28 Jan 2025 295.00 (3.15%) Pegang 280.30
RBC Capital 24 Jan 2025 324.00 (13.29%) Beli 275.42

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
11 Apr 2025 Pengumuman IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
03 Apr 2025 Pengumuman UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
08 Mar 2025 Pengumuman AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
05 Mar 2025 CNBC Amgen starts two critical late-stage trials for weight loss drug MariTide
04 Mar 2025 Pengumuman AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
01 Mar 2025 Pengumuman POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
28 Feb 2025 Pengumuman AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
20 Feb 2025 CNBC From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
14 Feb 2025 Pengumuman AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
07 Feb 2025 Pengumuman AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
04 Feb 2025 Pengumuman AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
31 Jan 2025 Pengumuman AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
17 Jan 2025 Pengumuman FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
Papar semua
Hasil Dividen (DY TTM) 3.19%
Purata Hasil Dividen 5T 3.06%
Nisbah Pembayaran 119.05%
Jangkaan Pembayaran Dividen Seterusnya Sep 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
16 May 2025 04 Mar 2025 06 Jun 2025 2.38 Tunai
14 Feb 2025 10 Dec 2024 07 Mar 2025 2.38 Tunai
18 Nov 2024 25 Oct 2024 09 Dec 2024 2.25 Tunai
16 Aug 2024 02 Aug 2024 06 Sep 2024 2.25 Tunai
16 May 2024 06 Mar 2024 07 Jun 2024 2.25 Tunai
15 Feb 2024 12 Dec 2023 07 Mar 2024 2.25 Tunai
16 Nov 2023 24 Oct 2023 08 Dec 2023 2.13 Tunai
17 Aug 2023 01 Aug 2023 08 Sep 2023 2.13 Tunai
17 May 2023 07 Mar 2023 08 Jun 2023 2.13 Tunai
14 Feb 2023 12 Dec 2022 08 Mar 2023 2.13 Tunai
16 Nov 2022 28 Oct 2022 08 Dec 2022 1.94 Tunai
17 Aug 2022 03 Aug 2022 08 Sep 2022 1.94 Tunai
16 May 2022 02 Mar 2022 08 Jun 2022 1.94 Tunai
14 Feb 2022 03 Dec 2021 08 Mar 2022 1.94 Tunai
15 Nov 2021 21 Oct 2021 08 Dec 2021 1.76 Tunai
16 Aug 2021 30 Jul 2021 08 Sep 2021 1.76 Tunai
14 May 2021 03 Mar 2021 08 Jun 2021 1.76 Tunai
11 Feb 2021 16 Dec 2020 08 Mar 2021 1.76 Tunai
13 Nov 2020 21 Oct 2020 08 Dec 2020 1.6 Tunai
14 Aug 2020 23 Jul 2020 08 Sep 2020 1.6 Tunai
15 May 2020 04 Mar 2020 08 Jun 2020 1.6 Tunai
13 Feb 2020 11 Dec 2019 06 Mar 2020 1.6 Tunai
14 Nov 2019 22 Oct 2019 06 Dec 2019 1.45 Tunai
14 Aug 2019 02 Aug 2019 06 Sep 2019 1.45 Tunai
16 May 2019 07 Mar 2019 07 Jun 2019 1.45 Tunai
14 Feb 2019 07 Dec 2018 08 Mar 2019 1.45 Tunai
15 Nov 2018 23 Oct 2018 07 Dec 2018 1.32 Tunai
16 Aug 2018 31 Jul 2018 07 Sep 2018 1.32 Tunai
16 May 2018 07 Mar 2018 08 Jun 2018 1.32 Tunai
14 Feb 2018 12 Dec 2017 08 Mar 2018 1.32 Tunai
16 Nov 2017 24 Oct 2017 08 Dec 2017 1.15 Tunai
15 Aug 2017 28 Jul 2017 08 Sep 2017 1.15 Tunai
15 May 2017 07 Mar 2017 08 Jun 2017 1.15 Tunai
13 Feb 2017 20 Dec 2016 08 Mar 2017 1.15 Tunai
14 Nov 2016 14 Oct 2016 08 Dec 2016 1 Tunai
15 Aug 2016 22 Jul 2016 08 Sep 2016 1 Tunai
13 May 2016 02 Mar 2016 08 Jun 2016 1 Tunai
11 Feb 2016 15 Dec 2015 08 Mar 2016 1 Tunai
12 Nov 2015 14 Oct 2015 07 Dec 2015 0.79 Tunai
13 Aug 2015 28 Jul 2015 08 Sep 2015 0.79 Tunai
12 May 2015 04 Mar 2015 05 Jun 2015 0.79 Tunai
10 Feb 2015 17 Dec 2014 06 Mar 2015 0.79 Tunai
10 Nov 2014 17 Oct 2014 05 Dec 2014 0.61 Tunai
12 Aug 2014 25 Jul 2014 05 Sep 2014 0.61 Tunai
13 May 2014 05 Mar 2014 06 Jun 2014 0.61 Tunai
11 Feb 2014 13 Dec 2013 07 Mar 2014 0.61 Tunai
12 Nov 2013 16 Oct 2013 06 Dec 2013 0.47 Tunai
14 Aug 2013 26 Jul 2013 06 Sep 2013 0.47 Tunai
14 May 2013 06 Mar 2013 07 Jun 2013 0.47 Tunai
11 Feb 2013 13 Dec 2012 07 Mar 2013 0.47 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 4.76 2 1.66
2024 9.00 4 3.45
2023 8.52 4 2.96
2022 7.76 4 2.96
2021 7.04 4 3.13
2020 6.40 4 2.78
2019 5.80 4 2.41
2018 5.28 4 2.71
2017 4.60 4 2.65
2016 4.00 4 2.74
2015 3.16 4 1.95
2014 2.44 4 1.53
2013 1.88 4 1.65
Papar semua
319.65319.65300.65300.65281.65281.65262.65262.65243.65243.65Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4Apr 7Apr 7Apr 8Apr 8Apr 9Apr 9Apr 10Apr 10Apr 11Apr 11

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
5.0005.0000.0000.000-5.000-5.000-10.000-10.000-15.000-15.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda